Enrolling! New Packaging Cell Line Early Access Program

iVexSol is excited to support innovation in CGT with our new Packaging Cell Line Early Access Program. Here’s how it works, and how you can enroll today.

LEXINGTON, Mass., May 6, 2023 -- Fast, effective cell and gene therapy development requires a truly flexible approach to lentiviral vector. iVexSol is honored to offer further support to the CGT sector with our new Packaging Cell Line Early Access Program.

What is the iVexSol Packaging Cell Line?

Our Packaging Cell Line provides a quick-start LVV kit for early-stage CGTs.

  • Pre-loaded with iVexSol’s proprietary accessory genes to jump-start LVV production
  • Single transfection required - Gene of Interest
  • Flexibility and speed for early-stage CGTs
  • Complements and works in tandem with our Producer Cell Lines

What are the benefits of iVexSol’s Stable LVV technology?

  • Unmatched Versatility. Our platform accommodates a wide range of Genes of Interest (GOIs)
  • Streamlined Production. Eliminate the time and resource burden of outsourcing or developing and maintaining your own packaging cell lines.
  • Enhanced Consistency. Benefit from a highly stable, robust cell line optimized for lentiviral vector production.
  • Reduced Costs. Focus on your core expertise in developing life-changing therapies – we'll handle the stable cell line generation.

What are the program criteria?

This Early Access program is open to companies in the IND-enabling stage or beyond, developing cell and gene therapies that utilize lentiviral vectors for gene delivery. All Genes oInterest (GOIs) are encouraged! Our platform is designed for flexibility and universal use.

Is there a screening process?

To ensure a successful program, iVexSol will conduct a brief screening process to assess your company's fit forthe program based on the following criteria:

  • Active development of a cell or gene therapy using lentiviral vectors.
  • Stage of development (IND-enabling or beyond).
  • Type of cell or gene therapy being developed (e.g., CAR-T programs).
  • Commitment to providing comprehensive feedback on performance.

Why should my organization consider enrolling? 

  • Be among the first to benefit from the efficiency and consistency of our Packaging Cell Line offering.
  • Gain valuable insights into how our platform can accelerate your development timeline.
  • Provide important feedback to help us optimize our service for the broader cell and gene therapy community.

Apply today

https://forms.office.com/r/m3QCEL348F

Once you submit this form, our team will review your application and contact you to discuss your eligibility for the program.

For more information, please contact Director of Business Development Kaytrina Anchelia at info@ivexsol.com.

Privacy Statement

We value your privacy. The information you provide will be used solely for the purposes of evaluating your company's fit for the Early Access Program and will not be shared with any third party.

 

 

 

Related Posts